Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial-Reference-Cited by-同舟云学术

Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTRA trial

Published:2010-05-05 Issue:10 Volume:69 Page:1789-1795
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Annals of the Rheumatic Diseases

Author:

Hetland M. L.,Stengaard-Pedersen K.,Junker P.,Ostergaard M.,Ejbjerg B. J.,Jacobsen S.,Lottenburger T.,Hansen I.,Tarp U.,Andersen L. S.,Svendsen A.,Pedersen J. K.,Lauridsen U. B.,Ellingsen T.,Lindegaard H.,Podenphant J.,Vestergaard A.,Jurik A. G.,Horslev-Petersen K.,

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Cited by 169 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differences in referral path, clinical and radiographic outcomes between seronegative and seropositive rheumatoid arthritis Mexican Mestizo patients: A cohort study;PLOS ONE;2024-06-06

2. Deep learning enables automatic detection of joint damage progression in rheumatoid arthritis—model development and external validation;Rheumatology;2024-04-10

3. Long-term efficacy of a 2-year MRI treat-to-target strategy on disease activity and radiographic progression in patients with rheumatoid arthritis in clinical remission: 5-year follow-up of the IMAGINE-RA randomised trial;RMD Open;2024-03

4. The prognostic value of 99mTc-glucosamine imaging in patients with rheumatoid arthritis: a single center prospective study;Nuclear Medicine Communications;2023-08-14

5. Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study;The Lancet Rheumatology;2023-05